StreetInsider.com News Articles

Form 425 Fulcrum Therapeutics, Filed by: Fulcrum Therapeutics, Inc.

Mon, 17 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260817/26938251.html

Form 425 Fulcrum Therapeutics, Filed by: Fulcrum Therapeutics, Inc.

Mon, 17 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260817/26938251.html

Form 425 Fulcrum Therapeutics, Filed by: Fulcrum Therapeutics, Inc.

Mon, 17 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26935405.html

Form 425 Fulcrum Therapeutics, Filed by: Fulcrum Therapeutics, Inc.

Mon, 17 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26935405.html

Form 425 Fulcrum Therapeutics, Filed by: Fulcrum Therapeutics, Inc.

Mon, 17 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26935389.html

Form 425 Fulcrum Therapeutics, Filed by: Fulcrum Therapeutics, Inc.

Mon, 17 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26935389.html

Form 8-K Fulcrum Therapeutics, For: Aug 16

Mon, 17 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26935353.html

Form 8-K Fulcrum Therapeutics, For: Aug 16

Mon, 17 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26935353.html

Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal

Mon, 17 Aug 2026 07:01:21 -0400

Fulcrum Therapeutics (Nasdaq: FULC) and Slate Medicines have entered into a definitive merger agreement in an all-stock transaction, according to a press release. The combined company will operate under the Slate Medicines name and is expected to trade on Nasdaq under the ticker symbol "SLTE."

Under the terms of the agreement, pre-merger Fulcrum stockholders are expected to own 5.0% of the combined company, while pre-merger Slate stockholders, including participants in a concurrent private placement, are expected to own 95.0%. Fulcrum is expected to contribute approximately $20.3 million in net cash to the combined entity and pay a cash dividend of an

Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal

Mon, 17 Aug 2026 07:01:21 -0400

Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal

Mon, 17 Aug 2026 07:01:21 -0400

Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal

Mon, 17 Aug 2026 07:01:21 -0400

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

Mon, 17 Aug 2026 07:00:00 -0400

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics

Slate’s lead product candidate, SLTE-1009, is a clinical stage, potentially best-in-class subcutaneous anti-PACAP/VIP monoclonal antibody for the preventative treatment of migraine

Concurrent oversubscribed private placement financing of $245 million from a leading syndicate of healthcare investors anticipated to fund operations into 2029

Companies to hold conference call on August 17, 2026, at 8:00 a.m. ET

CAMBRIDGE, Mass. and RALEIGH, N.C., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (“Fulcrum”) (Nasdaq: FULC) and

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

Mon, 17 Aug 2026 07:00:00 -0400

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics

Slate’s lead product candidate, SLTE-1009, is a clinical stage, potentially best-in-class subcutaneous anti-PACAP/VIP monoclonal antibody for the preventative treatment of migraine

Concurrent oversubscribed private placement financing of $245 million from a leading syndicate of healthcare investors anticipated to fund operations into 2029

Companies to hold conference call on August 17, 2026, at 8:00 a.m. ET

CAMBRIDGE, Mass. and RALEIGH, N.C., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (“Fulcrum”) (Nasdaq: FULC) and

Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932203.html

Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932203.html

Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260814/26932083.html

Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260814/26932083.html

Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: MONTANOVA CAPITAL, LLC

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931379.html

Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: MONTANOVA CAPITAL, LLC

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931379.html

Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26931349.html

Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26931349.html

Form 8-K Fulcrum Therapeutics, For: Aug 07

Mon, 10 Aug 2026 08:44:00 -0400

si-local-file:///var/storage/secattach/20260810/26895118.html

Form 8-K Fulcrum Therapeutics, For: Aug 07

Mon, 10 Aug 2026 08:44:00 -0400

si-local-file:///var/storage/secattach/20260810/26895118.html

Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: BANK OF AMERICA CORP /DE/

Mon, 03 Aug 2026 12:13:00 -0400

si-local-file:///var/storage/secattach/20260803/26856144.html